Condition
NMO Spectrum Disorder clinical trials and research
As of November 12, 2026, Find a Trial lists 7 NMO Spectrum Disorder clinical trials that are recruiting, at sites in 4 countries (most in China (5), Czechia (1), Germany (1)). By phase: Phase 1/2 (1), Early Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 7Clinical trials
- 4Countries
Newest NMO Spectrum Disorder clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Noninvasive transcranial temporal interference stimulation for neuropathic pain in NMOSD | — | Xi'an, Shaanxi | Recruiting | Jan 29, 2026 |
| BAFF‑R CAR T‑cell treatment for refractory neuroimmune diseases | Phase 1/2 | Tianjin, Tianjin Municipality | Recruiting | Jun 15, 2025 |
| Monoclonal antibody treatments for AQP4-positive neuromyelitis optica spectrum disorder | — | Wuhan, Hubei | Recruiting | Mar 20, 2025 |
| AI-assisted care for Multiple Sclerosis | — | Prague, Praha 2 and 2 other locations | Recruiting | Feb 28, 2024 |
| Evaluating B001 Injection for Neuromyelitis Optic Spectrum Disorder | Early Phase 1 | Beijing, Beijing Municipality and 3 other locations | Recruiting | Dec 6, 2021 |
| Collecting blood samples from patients undergoing plasma exchange | — | Iowa City, Iowa | Recruiting | Aug 13, 2021 |
| Observational study of neuroinflammation diseases in China | — | Beijing, Beijing Municipality | Recruiting | Sep 27, 2019 |
All recruiting trials (7)
-
Noninvasive transcranial temporal interference stimulation for neuropathic pain in NMOSD
Researchers will try noninvasive transcranial temporal interference stimulation to reduce chronic neuropathic pain in adults with neuromyelitis optica spectrum disorder (NMOSD).
-
BAFF‑R CAR T‑cell treatment for refractory neuroimmune diseases
This trial will try personalized BAFF‑R CAR T cells to reduce disease activity in people with hard‑to‑treat conditions such as CIDP, NMOSD, myasthenia gravis, and inflammatory myopathies.
-
Monoclonal antibody treatments for AQP4-positive neuromyelitis optica spectrum disorder
This registry will compare different monoclonal antibody therapies to see if they are safe and help adults in China who have AQP4-positive NMOSD.
-
AI-assisted care for Multiple Sclerosis
This study is testing whether using AI can help doctors better diagnose and treat people with Multiple Sclerosis by analyzing real-world data.
-
Evaluating B001 Injection for Neuromyelitis Optic Spectrum Disorder
This study is testing a new injection called B001 to see if it can help people with neuromyelitis optic spectrum disorder feel better and reduce their symptoms.
-
Collecting blood samples from patients undergoing plasma exchange
This study is collecting blood samples from patients with immune-related diseases who are having plasma exchange to see how their antibody levels change during treatment and to use the samples for future research.
-
Observational study of neuroinflammation diseases in China
This study is trying to see how brain and spinal cord changes in people with neuroinflammatory diseases can help us understand their condition better over a year of MRI scans.
Related topics
Quick answers
How many NMO Spectrum Disorder clinical trials are recruiting right now?
7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in China (5 trials), Czechia (1 trial), Germany (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 1, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.